This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Diabetes Mellitus  • Neurology  • Alert me on articles by topic

Bridget M. Kuehn

JAMA. 2006;296:380-381.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—New classes of diabetes drugs that mimic gut hormones may help patients with the disease battle persistent problems that conventional treatments alone are often unable to adequately control.

Even with treatment, patients with diabetes—particularly type 2 diabetes—may face spikes in blood glucose after meals, weight gain, and a loss of effectiveness of their treatments over time. But new agents that draw on a better understanding of how the body responds to meals—some already available, others in the development pipeline—may offer useful adjuncts to existing therapies (Riddle MC and Drucker DJ. Diabetes Care. 2006:29:435-449).

Increasing prevalence of diabetes, particularly type 2 diabetes, is spurring the search for better treatments. Strategies that target the gut hormones have shown some promise.

Two such therapies, exenatide and pramlintide, were approved last year by the US Food and Drug Administration. Three other drugs have had promising results in late clinical . . . [Full Text of this Article]

ON THE MARKET

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diabetes Mellitus--A Call for Papers
DeAngelis et al.
JAMA 2008;300:441-441.
FULL TEXT